Advertisement
Advertisement
CLDI
Calidi Biotherapeutics, Inc.
0.28
USDSponsored
+0.01
+2.44%
Apr 16, 15:59 UTC -4
Closed
After-Market
0.28
0.00
+1.37%
CLDI Earnings Reports
Positive Surprise Ratio
CLDI beat 6 of 10 last estimates.
60%
Next Report
Date of Next Report
--
Estimate for Q-- -- (Revenue/ EPS)
--
/--
Implied change from Q4 25 (Revenue/ EPS)
--
/--
Implied change from Q-- -- (Revenue/ EPS)
--
/--
Calidi Biotherapeutics, Inc. earnings per share and revenue
On Mar 27, 2026, CLDI reported earnings of -0.43 USD per share (EPS) for Q4 25, beating the estimate of -1.62 USD, resulting in a 73.59% surprise. Revenue reached --, compared to an expected --, with a --% difference. The market reacted with a -11.67% price change (close before vs. close after earnings).
Looking ahead to -- --, -- analysts forecast an EPS of -- USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Lexaria Bioscience Corp. Common Stock
Report Date
Apr 13, 2026 For Q2 26
Estimate
-$0.09
Actual
-$0.06
Surprise
+38.08%
Quince Therapeutics, Inc. Common Stock
Report Date
Apr 10, 2026 For Q4 25
Estimate
-$1.92
Actual
-$7.10
Surprise
-268.68%
Sunshine Biopharma Inc.
Report Date
Apr 03, 2026 For Q4 25
Estimate
-$0.27
Actual
-$0.54
Surprise
-96.08%
Nurix Therapeutics, Inc. Common stock
Report Date
Apr 08, 2026 For Q1 26
Estimate
-$0.76
Actual
-$0.79
Surprise
-2.68%
NovaBridge Biosciences - ADR
Report Date
Apr 07, 2026 For Q4 25
Estimate
-$0.05
Actual
-$0.28
Surprise
-421.58%
Scilex Holding Company Common Stock
Report Date
Apr 10, 2026 For Q4 25
Estimate
-$0.47
Actual
-$2.21
Surprise
-360.99%
FAQ
What were Calidi Biotherapeutics, Inc.'s earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, Calidi Biotherapeutics, Inc. reported EPS of -$0.43, beating estimates by 73.59%, and revenue of --, -- -- expectations.
How did the market react to Calidi Biotherapeutics, Inc.'s Q4 2025 earnings?
The stock price moved down -11.67%, changed from $0.27 before the earnings release to $0.24 the day after.
When is Calidi Biotherapeutics, Inc. expected to report next?
The next earning report is scheduled for --.
What are the forecasts for Calidi Biotherapeutics, Inc.'s next earnings report?
Based on --
analysts, Calidi Biotherapeutics, Inc. is expected to report EPS of -- and revenue of -- for Q-- --.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement